Coulter Sonali, Roberts Jason A, Hajkowicz Krispin, Halton Kate
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane.
Burns Trauma and Critical Care Research Centre, UQ Centre for Clinical Research, The University of Queensland, Brisbane.
Infect Dis Rep. 2017 Mar 30;9(1):6849. doi: 10.4081/idr.2017.6849.
This review sets out to evaluate the current evidence on the impact of inappropriate therapy on bloodstream infections (BSI) and associated mortality. Based on the premise that better prescribing practices should result in better patient outcomes, BSI mortality may be a useful metric to evaluate antimicrobial stewardship (AMS) interventions. A systematic search was performed in key medical databases to identify papers published in English between 2005 and 2015 that examined the association between inappropriate prescribing and BSI mortality in adult patients. Only studies that included BSIs caused by ESKAPE (, , , , and ) organisms were included. Study quality was assessed using the GRADE criteria and results combined using a narrative synthesis. We included 46 studies. Inappropriate prescribing was associated with an overall increase in mortality in BSI. In BSI caused by resistant gram positive organisms, such as methicillin resistant , inappropriate therapy resulted in up to a 3-fold increase in mortality. In BSI caused by gram negative (GN) resistant organisms a much greater impact ranging from 3 to 25 fold increase in the risk of mortality was observed. While the overall quality of the studies is limited by design and the variation in the definition of appropriate prescribing, there appears to be some evidence to suggest that inappropriate prescribing leads to increased mortality in patients due to GN BSI. The highest impact of inappropriate prescribing was seen in patients with GN BSI, which may be a useful metric to monitor the impact of AMS interventions.
本综述旨在评估当前关于不恰当治疗对血流感染(BSI)及相关死亡率影响的证据。基于更好的处方实践应带来更好的患者预后这一前提,BSI死亡率可能是评估抗菌药物管理(AMS)干预措施的一个有用指标。我们在主要医学数据库中进行了系统检索,以识别2005年至2015年期间发表的、探讨成年患者不恰当处方与BSI死亡率之间关联的英文论文。仅纳入了包括由ESKAPE(粪肠球菌、屎肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌)病原体引起的BSI的研究。使用GRADE标准评估研究质量,并采用叙述性综合分析合并结果。我们纳入了46项研究。不恰当处方与BSI患者的总体死亡率增加相关。在由耐甲氧西林金黄色葡萄球菌等耐革兰氏阳性菌引起的BSI中,不恰当治疗导致死亡率增加高达3倍。在由耐革兰氏阴性(GN)菌引起的BSI中,观察到的影响要大得多,死亡率风险增加3至25倍。虽然研究的总体质量受设计限制以及恰当处方定义的差异影响,但似乎有一些证据表明,不恰当处方会导致因GN BSI而住院的患者死亡率增加。不恰当处方的影响在GN BSI患者中最为明显,这可能是监测AMS干预措施影响的一个有用指标。